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The present study was undertaken to develop sustained release (SR) matrix tablets of losartan potassium, 
an angiotensin-II antagonist for the treatment of hypertension. The tablets were prepared by direct 
compression method, along with Kollidon SR as release retardant polymer. The amount of losartan 
potassium remains fixed (100 mg) for all the three formulations whereas the amounts of Kollidon SR 
were 250 mg, 225 mg, and 200 mg for F-1, F-2, and F-3 respectively. The evaluation involves three 
stages: the micromeritic properties evaluation of granules, physical property studies of tablets, and in-vitro 
release kinetics studies. The USP apparatus type II was selected to perform the dissolution test, and the 
dissolution medium was 900 mL phosphate buffer pH 6.8. The test was carried out at 75 rpm, and the 
temperature was maintained at 37 oC ± 0.5 oC. The release kinetics was analyzed using several kinetics 
models. Higher polymeric content in the matrix decreased the release rate of drug. At lower polymeric 
level, the rate and extent of drug release were enhanced. All the formulations followed Higuchi release 
kinetics where the Regression co-efficient (R2) values are 0.958, 0.944, and 0.920 for F-1, F-2, and F-3 
respectively, and they exhibited diffusion dominated drug release. Statistically significant (P<0.05) 
differences were found among the drug release profile from different level of polymeric matrices. The 
release mechanism changed from non-fickian (n=0.489 for F-1) to fickian (n=0.439 and 0.429 for F-2, 
and F-3 respectively) as a function of decreasing the polymer concentration. The Mean Dissolution Time 
(MDT) values were increased with the increase in polymer concentration.
Uniterms: Losartan potassium/sustained release/development. Losartan potassium/sustained release/
evaluation. Tablets/direct compression. Kollidon SR./use/release retardant.
O presente estudo foi realizado para desenvolver (SR) matriz de comprimidos de liberação sustentada de 
losartana, um antagonista da angiotensina II, para o tratamento da hipertensão arterial. Os comprimidos 
foram preparados pelo método de compressão direta com Kollidon SR como polímero de liberação 
lenta. A quantidade de losartana potássica permanece fixa (100 mg) para todas as três formulações 
enquanto que as quantidades de Kollidon SR foram de 250 mg, 225 mg e 200 mg para F-1, F-2 e F-3, 
respectivamente. A avaliação envolve três etapas- propriedades micromeríticas dos grânulos, estudo 
das propriedades físicas dos comprimidos e estudos de cinética de liberação in vitro.. Selecionoou-se 
o aparelho USP tipo II para realizar o teste de dissolução em meio com 900 mL de tampão fosfato 
pH 6,8 . O teste foi realizado em 75 rpm e a temperatura foi mantida a 37 oC ± 0.5 oC. Analisou-se a 
cinética de liberação utilizando-se vários modelos cinéticos. Conteúdo mais alto de polímero na matriz 
reduziu a taxa de liberação do fármaco. Em níveis mais baixos de polímero, a taxa e a extensão de 
liberação do fármaco foram aumentados. Todas as formulações seguiram a cinética de liberação de 
Higuchi, em que os valores do coeficiente de regressão (R2) foram 0,958 , 0,944 e 0,920 para F-1, F-2 
e F-3, respectivamente, e elas apresentaram liberação do fármaco dominada pela difusão. Encontraram-
se diferenças estatisticamente significativas (P<0,05) entre os perfis de liberação do fármaco com 
diferentes níveis de matrizes poliméricas. O mecanismo de liberação mudou de não-fickiano(n=0,489 
para F-1) para fickiano(n=0,439 e 0,429 para F-2 e F-3, respectivamente) em função da diminuição 
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da concentração de polímero. Os valores do Tempo de Dissolução Média (TDM) aumentaram com o 
aumento da concentração polímero.
Unitermos: Losartana/liberação sustentada/desenvolvimento. Losartana/liberação sustentada/avaliação. 
Comprimidos/compressão direta. Kollidon SR./uso/retardador de liberação.
diffuse outwards. Kollidon SR contains no ionic groups 
and is, therefore, inert to the drug substance (Reza, Quadir, 
Haider, 2003).
MATERIAL AND METHODS
Material
Losartan Potassium was kindly supplied by Globe 
Pharmaceuticals Limited, Noakhali, Bangladesh, as a gift 
sample. Kollidon SR was procured from BASF, Dhaka, 
Bangladesh Limited. Potassium di-hydrogen phosphate 
(Merck, Darmstadt, Germany), and sodium hydroxide 
(Merck, Darmstadt, Germany) were used as dissolution 
medium. Magnesium stearate and lactose were obtained 
from Novo Healthcare Limited, Dhaka, Bangladesh. 
Solvents and all other chemicals were of analytical grade.
Methods
Preparation of matrix tablet
Various methods are available for producing sus-
tained release Losartan Potassium tablet preparation. In 
our experiment, direct compression technique was fol-
lowed to prepare sustained release Losartan Potassium 
matrix tablet from the formulations mentioned in Table I.
The active ingredient (losartan potassium), release 
retardant (Kollidon SR), filler (lactose), and lubricant 
(magnesium stearate) were blended together by dry mix-
ing. The dried granules were then sized through 40-mesh 
sieve. Finally, the granules were weighed to adjust the 
TABLE I - Proposed formulations for sustained release losartan 
potassium matrix tablet
Ingredients
Amount (mg)
F-1 F-2 F-3
Losartan Potassium 100 100 100
Kollidon SR 250 225 200
Lactose 0 25 50
Magnesium stearate 3 3 3
Total 353 353 353
INTRODUCTION
The objective of an ideal drug delivery system is to 
deliver adequate amount of drug for an extended period 
for its optimum therapeutic activity. Most drugs are inher-
ently not long-lasting in the body, and require multiple 
daily dosing to achieve the desired blood concentration to 
produce therapeutic activity. To overcome such problems 
greater attention has been focused on sustained release 
drug delivery system (Chien, 1992).
Losartan potassium is an orally active angiotensin-II 
receptor antagonist used in the treatment of hypertension 
due to mainly blockade of AT1 receptor. It is freely soluble 
in water, slightly soluble in acetonitrile, and soluble in 
isopropyl alcohol. It is readily absorbed from the gastroin-
testinal tract with oral bioavailability of about 33 per cent 
and a plasma elimination half-life ranging from 1.5 to 2.5 
hours. Administration of losartan potassium in a sustained 
release dosage form with dual characteristics, that is, burst 
release, followed by an extended release over 8 hours 
would be more desirable; as these characteristics would al-
low a rapid onset followed by protracted anti-hypertensive 
effect by maintaining the plasma concentration of the drug. 
Previously, several studies were conducted on losartan 
potassium by using various hydrophilic and hydrophobic 
polymers for their in-vitro evaluation (Chithaluru et al., 
2011; Shanmugam et al., 2011).
The objective of the present investigation were to 
prepare sustained release matrix tablets of losartan Potas-
sium by using Kollidon SR at three different concentra-
tions, and to compare the in-vitro characteristics (weight 
variation, thickness and diameter, hardness, friability, drug 
content, release kinetics, etc.) of the developed matrix tab-
lets. Kollidon SR is polyvinyl acetate and povidone based 
matrix-retarding agent. Polyvinyl acetate is insoluble in 
water. The povidone content is gradually leached out after 
introduction into water. Kollidon SR is completely soluble 
in N-methylpyrrolididone. It is particularly suitable for 
the manufacture of pH independent sustained release 
matrix tablets. Polyvinyl acetate is a plastic material that 
produces a coherent matrix even under low compression 
forces. When the tablets are introduced into gastric or 
intestinal fluid, the water-soluble povidone is leached out 
to form pores through which the active ingredient slowly 
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final weight of individual tablet considering its loss during 
operational handling. Then, the granules were made into 
tablets by direct compression at fixed compression force 
(5 ton) for specific period of time (2 minutes) by using 
hydraulic press (PIKE Technologies, India; Model: M-15) 
fitted with 13 mm dies.
Micromeritic properties of granules
·	 Bulk density
LBD (loose bulk density) and TBD (tapped bulk den-
sity) were determined by 5 g of powder from each formu-
la—previously lightly shaken to break any agglomerates 
formed; and was placed into a 10 ml measuring cylinder. 
After the initial volume was observed, the cylinder was 
allowed to fall under its own weight onto a hard surface 
from a height of 2.5 cm at 2-second intervals. The reading 
of tapping was continued until no further change in volume 
was noted. LBD and TBD were determined by using fol-
lowing equations (Shah, Rampradhan, 1997):
LBD = Weight of the powder (W) /volume of the packing 
(V)
TBD = Weight of the powder/Tapping volume of the 
packing
·	 Carr’s index
The Carr’s Index (CI) is an indication of the com-
pressibility of a powder. It is calculated by the formula:
CI = {(BD-TD)/BD} x 100
where, BD is the freely settled bulk density of the powder, 
and TD is the tapped bulk density of the powder (Rawlins, 
1977).
·	 Hausner’s ratio
The Hausner’s ratio is a number that is correlated 
to the flowability of powder or granular material. It is 
calculated by:
H = BD/TD
where, BD is the freely settled bulk density of the powder, 
and TD is the tapped bulk density of the powder (Grey, 
Beddow, 1969; Li, 2004; Conesa, 2004; Rough, Wilson, 
York, 2005).
·	 Angle of repose
The angle of repose of granules was determined by 
the funnel method. The accurately weighed granules 
were taken in a funnel. The height of the funnel was ad-
justed in such a way that the tip of the funnel just touched 
the apex of the heap of the granules. The granules were 
allowed to flow through the funnel freely onto the surface. 
The diameter of the powder cone was measured, and angle 
of repose was calculated using (Botz et al., 2003):
Angle of repose θ = tan-1 (h/r)
where, ‘h’ is height of the powder cone, and ‘r’ is the radius 
of the powder cone.
Physical parameters and drug content
·	 Weight variation
For weight variation test, the weights of 10 tablets 
(Electronic balance AR2140, India) of each batch were 
taken individually, and calculated the average weight of 
10 tablets of each batch. Then the percentage of weight 
variation was determined of each tablet by using (Rashid 
et al., 2009):
% Weight variation = {(Average weight – Individual wei-
ght)/Average weight} × 100
·	 Thickness and diameter
The thickness and diameter of the tablets of all of the 
three formulations were determined with digital calipers 
(Range: 0-150 mm).
·	 Hardness
Tablet hardness was determined with tablet hard-
ness tester EH-OIP Electrolab, India (Kaushik, Dureja, 
Saini, 2004).
·	 Friability
The friability of the tablets was measured in a Roche 
friabilator (EF2 Electrolab, India). Tablets of a known 
weight (W1) were de-dusted in a drum for a fixed time 
(25 rpm for 4 minutes), and weighed (W2) again. The 
weight loss should not be more than 1 per cent (Reddy et 
al., 2011). 
Friability = {(W1 – W2)/W1} × 100
·	 Drug content
10 tablets were weighed and powdered; then, 
176.5 mg tablet powder (equivalent to 100 mg) was dis-
solved in buffer solution and made the volume up to 
100 mL. The solution was diluted 100 times, and absor-
bance was measured at 205 nm by using SHIMADZU 
UV-1800 spectrophotometer, Japan; and drug content was 
determined (Mansoor, Sharma, Dhakal, 2007).
In vitro release studies
·	 Dissolution study procedure
The in-vitro dissolution studies were performed 
using USP type-IΙ dissolution apparatus (Rotating Peddle 
method) at 75 rpm. The dissolution medium consisted of 
potassium di-hydrogen phosphate buffer of pH 6.8 up to 
900 mL, maintained at 37 oC ± 0.5 oC; where the tablets 
were completely in sink condition in the dissolution vessel. 
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An aliquot (5 ml) was withdrawn at specific time intervals, 
which replaced by equivalent amount of buffer solution. 
The drug content was determined by UV-visible spectro-
photometer (SHIMADZU UV-1800 spectrophotometer) at 
205 nm. The release studies were conducted in triplicate.
·	 Drug release kinetics
To analyze the mechanism of drug release from the 
matrix tablets, the release data were fitted to the following 
equations:
Zero-order equation: (Cooper and Gunn, 1986) Q = k0 t
where, Q is the amount of drug released at time t, and k0 
is the release rate.
First-order equation (Hadjiioannou, Christian, Koup-
paris, 1993):
Log Q = Log Q0 – k1t/ 2.303
where, Q is the amount of drug un-dissolved at t time, Q0 
is drug concentration at t = 0 and k1 is the release rate 
constant. 
Higuchi’s equation (Higuchi, 1963);
Q = k2t1/2
where, Q is the percent of drug release at time t, and k2 is 
the diffusion rate constant.
Hixson-Crowell equation:
Qo1/3 - Qt 1/3 = Kot
where, Qt is the initial amount of drug, Qo is cumulative 
amount of drug release at time t, Ko is Hixson-Crowell 
release constant and t is time in hours. 
Korsmeyer-Peppas equation (Korsmeyer et al., 
1983):
Log (M t / M f) = Log k + n Log t
where, Mt is the amount of drug release at time t; Mf is the 
amount of drug release after infinite time; k is a release 
rate constant incorporating structural and geometric char-
acteristics of the tablet; and n is the diffusional exponent 
indicative of the mechanism of drug release.
To clarify the diffusion exponent (n) for different 
batches of matrix tablet, the log value of percentage drug 
released was plotted against log time for each batch. A 
value of n ≤ 0.45 indicates Fickian (case I) release; > 0.45 
but < 0.89 for non-Fickian (anomalous) release; and > 0.89 
indicates super case II type of release. Case II generally 
refers to the erosion of the polymeric chain, and anomalous 
transport (Non-Fickian) refers to a combination of both 
diffusion and erosion-controlled drug release (Shato et 
al., 1997). Mean dissolution time (MDT) was calculated 
from dissolution data using the equation: (Mockel, Lip-
pold, 1993)
MDT = (n / n + 1) k -1/n
where, n = diffusion exponent and k = release rate con-
stant.
RESULTS AND DISCUSSION
The Micromeritic properties of granules are in-
dicated in Table II. The results of bulk densities were 
0.522, 0.459, and 0.454 g/mL and the results of tapped 
bulk densities were 0.669, 0.677, and 0.708 g/mL for F-1, 
F-2, and F-3 respectively. The bulk densities of granules 
of the proposed formulation F-1 were quite higher than 
that of other granules. This may be due to the presence of 
more fine granules (Nellore et al., 1998). The Hausner’s 
Ratio for F-1, F-2, and F-3 were 1.34, 1.49, and 1.54 
respectively. A Hausner’s Ratio greater than 1.25 is con-
sidered an indication of poor flowability (Li, 2004). The 
angle of repose for F-1, F-2, and F-3 were 50˚, 48.7˚, and 
45.6˚ respectively. The results of angle of repose (> 30) 
indicate unsatisfactory flow properties of granules (Rashid 
et al., 2009). A Carr’s Index greater than 25 is considered 
an indication of poor flowability, and below 15 is of good 
flowability (Patel, Baria, 2009).
The mechanical properties of the Losartan Potassi-
um tablets were improved (increased hardness and reduced 
friability) as the polymer concentration were increased. 
The produced tablets had thickness (n=3) about 3±0.01 
mm, and diameter (n=3) of about 13 mm. Therefore, the 
polymer and other additives had no effect on the dimen-
sions (thickness and diameter) of the Losartan Potassium 
matrix tablet, if the total weight is same, and the die and 
punch size is fixed. The weight variation (n=10) test of the 
tablet meet the USP specification as indicated in Table II.
To establish the sink condition, we did not carry out 
the experiment directly, but in some reports (Bonfilio et 
al., 2010) have stated that the drug does not possess suf-
ficient solubility in 0.1 N hydrochloric acid, whereas, it 
shows satisfactory solubility in phosphate buffer. In some 
reports (Bonfilio et al., 2010), it has been stated that the use 
of water as a dissolution medium is discouraged because 
test condition such as pH and surface tension can vary 
depending on water source, and may change during the 
dissolution test itself. For this reason, the phosphate buffer 
pH 6.8 was chosen as dissolution medium.
The calibration curve of analytical method exhibited 
excellent linearity (R2 = 0.996) within the range of 1 μg/mL 
to 10 μg/mL. For the UV spectroscopic method, the rela-
tive standard deviation (RSD) values for intraday system 
and method precision were 0.25 and 1.04 per cent, respec-
tively. The specificity study indicated that no interference 
from the matrix and excipients was found in the placebo of 
the tablets. The sample was found to be stable at 25 oC for 
24 h and the overall RSD percentage was found to be 0.99.
The drug content (n=3) of the formulated tablet 
among different batches ranged from 99.7±1.2% to 
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TABLE II- Micromeritic properties of granules and physical parameters of tablets
Code F-1 F-2 F-3
Bulk Density (g/mL) 0.522 0.459 0.454
Tap density (g/mL) 0.669 0.677 0.708
Carr’s Index (%) 21.99 32.07 35.89
Hausner’s ratio 1.28 1.49 1.54
Angle of repose 50˚ 48.7˚ 45.6˚
Average Weight *±SEM 355.88±1.16 353.78±0.68 352.59±0.35
Thickness (mm)**±SEM 3±0.01 3.01±0.01 3±0.01
Diameter (mm)**±SEM 13±0 13±0 13±0
Hardness (Kf)**±SEM 26.37±0.01 22.82±0.17 20.34±0.29
Friability (%)**±SEM 0.02±0.00 0.04±0.01 0.05±0.01
Drug content (%)**±SEM 99.7±1.2 101.33±0.8 102.5±1.3
*(n=10) and ** (n=3)
TABLE III – In-vitro drug release kinetics for proposed formulations of Losartan Potassium sustained release matrix tablet
Code
Regression co-efficient (R2) value Release rate constant (k)
Diffusion 
exponent (n)
Release type
Zero order 1st order Higuchi Hixson-Crowell
Korsmeyer-
Peppas Higuchi
Korsmeyer-
Peppas
F-1 0.808 0.898 0.958 0.466 0.946 0.316 0.489 Non-Fickian
F-2 0.782 0.918 0.944 0.439 0.954 0.396 0.439 Fickian
F-3 0.753 0.911 0.920 0.437 0.940 0.439 0.429 Fickian
102.5±1.3% which meet USP specification (100±5%). It 
was noticed that Kollidon SR has a unique character of 
maintaining tablets geometric shape (Sakr, Alanazi, 2011). 
This is one of the most common reasons for choosing the 
Kollidon SR as release retardant polymer as compared to 
all others hydrophobic polymer.
To know the mechanism of drug release from these 
formulations, the data were treated according to zero order 
(cumulative amount of drug released vs time), first-order 
(log cumulative percentage of drug remaining vs time), 
Higuchi’s (cumulative percentage of drug released vs 
square root of time), Korsmeyer-Peppas (log cumulative 
percentage of drug released vs log time), and Hixson-
Crowell (cubic root of percent drug release vs time) pat-
tern for kinetics of drug release during dissolution process 
(Reddy, Mutalik, 2003).
As clearly indicated in Table III, the formulations did 
not follow a zero-order release pattern (Figure 1) where 
the regression values are 0.808, 0.782, and 0.753 for F-1, 
F-2, and F-3 respectively. When the data were plotted ac-
cording to the first-order equation, the tablets showed a 
first order release, with regression value of 0.898, 0.918, 
and 0.911. The formulations showed to be best expressed 
by Higuchi’s equation, as the plots showed high linearity 
with regression value of 0.958, 0.944, 0.920 for Kollidon 
SR, indicating that the drug releases follow the Higuchi 
release kinetics (Figure 2), and diffusion is the dominating 
drug release mechanism. This finding is similar to that of 
previously investigated work (Reza, Quadir, Haider, 2003; 
Shanmugam et al., 2011).
The dissolution data was also fitted to the well-
known exponential equation (Korsmeyer-Peppas equa-
tion), which is often used to describe the drug release 
behavior from polymeric systems. As indicated in the 
Table III, F-1 exhibited non-fickian type drug release, 
whereas, F-2 and F-3 exhibited fickian-type drug release 
from the tablet matrix. The percentage of drug release 
differs significantly at P<0.05 from different amount of 
polymer matrices.
MDT values are used to characterize drug release 
rate from a dosage form and release retarding efficiency 
of the polymer. MDT value is higher for F-1 and lower 
for F-3 as shown in Table IV. Moreover, we calculated 
the t75% values for all batches, and the data showed marked 
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enhancement of t75% values from 3.64 to 7.93 (Table IV) 
indicating that the F-1 is the best formulation among the 
developed formulations. This finding indicates consider-
able release retarding potentiality of the Kollidon SR that 
was also reported by previous work (Sakr, Alanazi, 2011). 
The relationship between release rate and polymer content 
is shown in Figure 3.
CONCLUSION
The release rate of losartan potassium decreased 
with increase in polymer concentration. Therefore, it can 
be concluded that Kollidon SR is potential candidates for 
the development of sustained release losartan potassium 
matrix tablets. The best-proposed formulation F-1 may 
be used for the development of sustained release losartan 
potassium matrix tablet to meet the patient’s demand for 
the management of hypertension.
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